 VIENNA, Austria, July 27, 2021 GLOBE NEWSWIRE -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies SAITs, today announced that AC Immune SA NASDAQ: ACIU, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS AFFITOME technology. 